Please login to the form below

Not currently logged in

New appointment at Synexus

Synexus has appointed Jeremy Hickling as senior vice president of portfolio management

Synexus has appointed Jeremy Hickling as senior vice president of portfolio management. Jeremy has 11 years' industry experience and brings significant, senior level knowledge to his new role.

Michael Fort, Synexus' chief executive, said: "We had a very successful and exciting 2009, culminating in our acquisition of ClinPharm in Germany. With Jeremy on board, it is important that we continue to expand our business development by demonstrating to a wider audience how we can help pharma, biotechs and CROs reduce costs and speed up clinical trials."

Jeremy, was previously a senior director within the late phase PACE group for leading contract research organisation PAREXEL where he was responsible for key projects and relationship management, study design and strategy. Prior to this he worked as the head of UK planning and operations for Biogen Idec Inc.

Jeremy said: "I've been very fortunate to work for some of the best organisations in the pharma industry. The opportunity to work with Synexus gives me the chance to be involved with a company that is not only growing rapidly, but is also making real changes to the clinical trials industry. I am keen to be a part of that and to demonstrate the real benefits the Synexus model offers to pharma and CRO clients alike."

Synexus is based outside Manchester and is the world's largest multinational organisation specialising in the recruitment of patients and the running of trials at its own dedicated research centres.

19th January 2010


Featured jobs

Subscribe to our email news alerts


Add my company
Skills in Healthcare

At Skills in Healthcare, we are able to provide our customers with a professional set of sales capabilities. With our...

Latest intelligence

The rise of real-world evidence
Demonstrating efficacy and value requires more than clinical trial data...
Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?